Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?
Date
2017Journal
Expert Opinion on PharmacotherapyPublisher
Taylor and Francis LtdType
Article
Metadata
Show full item recordIdentifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018329702&doi=10.1080%2f14656566.2017.1323878&partnerID=40&md5=fcaf11a4f015d05842d325ad9e9d2f95; http://hdl.handle.net/10713/9965ae974a485f413a2113503eed53cd6c53
10.1080/14656566.2017.1323878
Scopus Count
Collections
Related articles
- Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
- Authors: Rascati KL, Worley K, Meah Y, Everhart D
- Issue date: 2017 Mar
- Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
- Authors: Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF
- Issue date: 2015 Oct
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
- Authors: Scheen AJ
- Issue date: 2013 May
- Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
- Authors: Scheen AJ
- Issue date: 2010 Sep
- Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
- Authors: Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K
- Issue date: 2013